WATCH: Israeli drug doubles survival time for patients with brain tumors

March 30, 2017

Professor Dror Harats, M.D., CEO of VBL Therapeutics, describes Phase III clinical trials of a cancer treatment in which a virus is injected intravenously and cuts off blood supply to solid tumors, shrinking cancerous growths.

brain tumors cancer treatment Dror Harats solid tumors VBL Therapeutics virus

WATCH: Israeli drug doubles survival time for patients with brain tumors

Send To Friend